Y-biologics Inc.

Medpacto Inc.

Biocomplete Inc.

Yeung Chul Kim

Young Woo Park

Bum-chan Park

Seok Ho Yoo

Jae Eun Park

Young-Gyu Cho

Jung Chae Lim

Gi Sun Baek

Si Hyung Lee

Jisu Lee

Hye Nan Kim

Hyun Mi Lee

Il Ho Ha

Youngja Song

Ji-Young Shin

Sang Pil Lee

Yunseon Choi

Sunha Yoon

Soo A Choi

Ju Ry Lim

Bum-Chan Park

The present invention relates to an antibody against delta-like 1 homolog () (DLK1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, an antibody drug conjugate (ADC) comprising the same, a pharmaceutical composition for treating cancer, a composition for diagnosing cancer, and a chimeric antigen receptor (CAR) and a T-cell engager comprising the same.

Antibody against human DLK1 and use thereof

Disclosed are an antibody to human programmed cell death-ligand 1 (PD-L1) or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vector, a method for producing the antibody or an antigen-binding fragment thereof, and a composition for preventing or treating cancer or infectious diseases containing the same.

Antibody to programmed death-ligand 1 (PD-L1) and use thereof

Provided are a modified DKK2 polypeptide according to an aspect, a nucleic acid encoding the same, a preparation method thereof, and use thereof. Accordingly, a modified DKK2 protein having an additional glycosyl group or improved binding affinity for a substrate LRP6 may be efficiently prepared, thereby being used for promoting angiogenesis or preventing or treating vascular permeability-related diseases.

Modified DKK2 protein, nucleic acid encoding the same, preparation method thereof, and use thereof

Growing community of inventors

Daejeon, South Korea

Yeung Chul Kim